Heterocyclic Compounds, 4 or More Rings
"Heterocyclic Compounds, 4 or More Rings" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of heterocyclic compounds that include four or more fused rings. Both aromatic or non-aromatic ring structures are included in this category.
| Descriptor ID |
D006576
|
| MeSH Number(s) |
D03.633.400
|
| Concept/Terms |
Heterocyclic Compounds, 4 or More Rings- Heterocyclic Compounds, 4 or More Rings
- Heterocyclic Compounds with 4 or More Rings
- Heterocyclic Cpds, 4 or More Rings
- Heterocyclic Compounds with Four or More Rings
Heterocyclic Compounds, 5-Ring- Heterocyclic Compounds, 5-Ring
- 5-Ring Heterocyclic Compounds
- Heterocyclic Compounds, 5 Ring
- Heterocyclic Cpds, 5 Ring
- Five Ring Heterocyclic Compounds
- Fused Heterocyclic Compounds, Five-Ring
- Fused Heterocyclic Compounds, Five Ring
Heterocyclic Compounds, 4-Ring- Heterocyclic Compounds, 4-Ring
- 4-Ring Heterocyclic Compounds
- Heterocyclic Compounds, 4 Ring
- Heterocyclic Cpds, 4 Ring
- Four Ring Heterocyclic Compounds
- Fused Heterocyclic Compounds, Four-Ring
- Fused Heterocyclic Compounds, Four Ring
|
Below are MeSH descriptors whose meaning is more general than "Heterocyclic Compounds, 4 or More Rings".
Below are MeSH descriptors whose meaning is more specific than "Heterocyclic Compounds, 4 or More Rings".
This graph shows the total number of publications written about "Heterocyclic Compounds, 4 or More Rings" by people in this website by year, and whether "Heterocyclic Compounds, 4 or More Rings" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 2 | 0 | 2 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 1 | 2 |
| 2017 | 3 | 1 | 4 |
| 2018 | 1 | 1 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 2 | 3 |
| 2021 | 2 | 1 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 2 | 1 | 3 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Heterocyclic Compounds, 4 or More Rings" by people in Profiles.
-
Localized inflammasome inhibition mitigates foreign body response to subcutaneous long-acting antiretroviral therapy for HIV. J Control Release. 2026 Feb 10; 390:114559.
-
Bictegravir Use During Pregnancy: A Multicenter Retrospective Analysis Evaluating HIV Viral Suppression and Perinatal Outcomes. Clin Infect Dis. 2024 11 22; 79(5):1258-1261.
-
Birth outcomes following bictegravir exposure during pregnancy. AIDS. 2025 Mar 15; 39(4):381-386.
-
Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection. J Pediatr Gastroenterol Nutr. 2024 Jun; 78(6):1342-1354.
-
Efficacy and safety of pan-genotypic sofosbuvir and velpatasvir in patients with hepatitis C and HIV coinfection on?dolutegravir-based antiretroviral therapy. J Viral Hepat. 2023 09; 30(9):740-745.
-
Sofosbuvir plus velpatasvir combination for the treatment of chronic hepatitis C in patients with end stage renal disease on renal replacement therapy: A systematic review and meta-analysis. Nephrology (Carlton). 2022 Jan; 27(1):82-89.
-
The Cyclin-Dependent Kinase 8 (CDK8) Inhibitor DCA Promotes a Tolerogenic Chemical Immunophenotype in CD4+ T Cells via a Novel CDK8-GATA3-FOXP3 Pathway. Mol Cell Biol. 2021 08 24; 41(9):e0008521.
-
Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end-stage renal disease on maintenance haemodialysis. Liver Int. 2021 04; 41(4):705-709.
-
Cost-effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis. J Viral Hepat. 2021 02; 28(2):260-267.
-
Targeting the NLRP3 Inflammasome With Inhibitor MCC950 Prevents Aortic Aneurysms and Dissections in Mice. J Am Heart Assoc. 2020 04 07; 9(7):e014044.